OVERCOMING RESISTANCE TO NK-MEDIATED LYSIS IN ENZALUTAMIDE-RESISTANT PROSTATE CANCER CELLS

被引：0
|
作者：
Dahut, Madeline [1 ]
Fousek, Kristen [1 ]
Horn, Lucas [1 ]
Qin, Haiyan [1 ]
Schlom, Jeffrey [1 ]
Palena, Claudia [1 ]
机构：
[1] Natl Canc Inst, Bethesda, MD USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷
关键词：
D O I：
10.1136/jitc-2022-SITC2022.0909
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
909
引用
收藏
页码：A947 / A947
页数：1
相关论文
共 50 条
  • [21] Knockdown of EPS8 expression attenuates the proliferation of enzalutamide-resistant prostate cancer cells
    Huang, Wei-Lun
    Chen, Sih-Han
    Wu, Richard Chen-Yu
    Mai, Hsing-Cha
    Wu, Chun-Hsien
    Hsieh, Pei-Fang
    Pang, See-Tong
    Lin, Victor Chia-Hsiang
    AMERICAN JOURNAL OF CANCER RESEARCH, 2024, 14 (10):
  • [22] Prostate cancer RIPTAC™ therapeutics demonstrate activity in preclinical models of Enzalutamide-resistant prostate cancer
    Yu, Xinheng
    Eastman, Kyle J.
    Raina, Kanak
    Jones, Kelli M.
    Forbes, Chris D.
    Hundt, Abigail
    Garcia, Marco
    Stronk, Rebecca
    Howard, Katia
    McGovern, Andrew
    Chenard, Rebekka
    Denny, Allison
    Forgione, Mia
    Bassoli, Kyle
    Garvin, Ethan
    Mousseau, James J.
    Li, Hao
    King, Madeline P.
    Bhardwaj, Amit
    Kayser-Bricker, Katherine J.
    Crews, Craig M.
    CANCER RESEARCH, 2023, 83 (07)
  • [23] Integrative transcriptional analysis of enzalutamide-resistant castration resistant prostate cancer cells using RNA sequencing.
    Kim, Tae Heon
    Kang, Minyong
    Oh, Ji Youn
    Kang, Yumi
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [24] Overcoming EGFR-induced resistance to enzalutamide in castration-resistant prostate cancer
    Steele, Thomas M.
    Jathal, Maitreyee K.
    Siddiqui, Salma
    Ghosh, Paramita M.
    CANCER RESEARCH, 2016, 76
  • [25] Mechanisms and Approaches for Overcoming enzalutamide Resistance in Prostate Cancer
    Ark, Alexandra Vander
    Cao, Jingchen
    Li, Xiaohong
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [26] Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants
    Shiota, Masaki
    Dejima, Takashi
    Yamamoto, Yoshiaki
    Takeuchi, Ario
    Imada, Kenjiro
    Kashiwagi, Eiji
    Inokuchi, Junichi
    Tatsugami, Katsunori
    Kajioka, Shunichi
    Uchiumi, Takeshi
    Eto, Masatoshi
    CANCER SCIENCE, 2018, 109 (10) : 3224 - 3234
  • [27] MCT INHIBITION AS A POTENTIAL THERAPEUTIC STRATEGY TO TARGET ENZALUTAMIDE-RESISTANT PROSTATE CANCER
    Bhattacharjee, Sayani
    Doan, Jonathan P.
    Pletcher, Jerred P.
    Wynn, Rebecca
    Petros, Firas
    Sindhwani, Puneet
    Nadiminty, Nagalakshmi
    JOURNAL OF UROLOGY, 2020, 203 : E767 - E767
  • [28] Ralaniten Sensitizes Enzalutamide-Resistant Prostate Cancer to Ionizing Radiation in Prostate Cancer Cells that Express Androgen Receptor Splice Variants
    Banuelos, Carmen A.
    Ito, Yusuke
    Obst, Jon K.
    Mawji, Nasrin R.
    Wang, Jun
    Hirayama, Yukiyoshi
    Leung, Jacky K.
    Tam, Teresa
    Tien, Amy H.
    Andersen, Raymond J.
    Sadar, Marianne D.
    CANCERS, 2020, 12 (07) : 1 - 17
  • [29] A Pyrrole-Imidazole Polyamide Is Active against Enzalutamide-Resistant Prostate Cancer
    Kurmis, Alexis A.
    Yang, Fei
    Welch, Timothy R.
    Nickols, Nicholas G.
    Dervan, Peter B.
    CANCER RESEARCH, 2017, 77 (09) : 2207 - 2212
  • [30] MCT inhibition as a therapeutic strategy to target Enzalutamide-resistant prostate cancer.
    Bhattacharjee, Sayani
    Doan, Jonathan
    Wynn, Rebecca
    Nadiminty, Nagalakshmi
    CANCER RESEARCH, 2021, 81 (13)
12345